Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors
- PMID: 25429521
- DOI: 10.1378/chest.14-2414
Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors
Abstract
Background: Recent findings suggest that patients with atrial fibrillation (AF), in addition being at thromboembolic risk, are at risk of myocardial infarction (MI). Our aim was to investigate predictors of MI and cardiovascular death in a cohort of patients with AF who were taking anticoagulants.
Methods: We prospectively followed up 1,019 patients with AF for a median of 33.7 months (3,223 person-years). All patients were treated with oral vitamin K antagonists. Primary outcome was a composite end point of cardiovascular events (CVEs) including fatal/nonfatal MI, cardiac revascularization, and cardiovascular death.
Results: The mean age of the patients was 73.2 years, and 43.8% were women. At follow-up, 111 CVEs (3.43%/y) had occurred: 47 fatal-nonfatal MI/revascularization and 64 cardiovascular deaths. In addition, 31 stroke/transient ischemic attacks (0.96%/y) were recorded. Patients experiencing CVEs were older (P < .001) and had a higher prevalence of metabolic syndrome (MetS) (P = .005), heart failure (P = .001), and prior cardiac (P < .001) and cerebrovascular events (P < .001). On a Cox proportional hazard analysis, age (hazard ratio [HR], 1.083; 95% CI, 1.053-1.113; P < .001), smoking (HR, 2.158; 95% CI, 1.193-3.901; P = .011), history of cerebrovascular (HR, 1.704; 95% CI, 1.119-2.597; P = .013) and cardiac (HR, 1.658; 95% CI, 1.105-2.489; P = .015) events, MetS (HR, 1.663; 95% CI, 1.107-2.499; P = .014), heart failure (HR, 1.584; 95% CI, 1.021-2.456; P = .040), and male sex (HR, 1.499; 95% CI, 1.010-2.223; P = .044) predicted CVEs.
Conclusions: Patients with AF still experience a high rate of CVEs despite receiving anticoagulant treatment. MetS is a common clinical feature in patients with AF, which increases the risk of CVEs. A holistic approach is needed to reduce the cardiovascular risk in patients with AF.
Trial registry: ClinicalTrials.gov; No.: NCT01882114; URL: www.clinicaltrials.gov.
Similar articles
-
Family History of Atrial Fibrillation and Risk of Cardiovascular Events: A Multicenter Prospective Cohort Study.Circ Arrhythm Electrophysiol. 2020 Sep;13(9):e008477. doi: 10.1161/CIRCEP.120.008477. Epub 2020 Jul 27. Circ Arrhythm Electrophysiol. 2020. PMID: 32718257
-
Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.Int J Cardiol. 2015 Dec 15;201:513-6. doi: 10.1016/j.ijcard.2015.08.054. Epub 2015 Aug 5. Int J Cardiol. 2015. PMID: 26318513
-
Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation.Am Heart J. 2015 Sep;170(3):490-7.e1. doi: 10.1016/j.ahj.2015.05.011. Epub 2015 May 22. Am Heart J. 2015. PMID: 26385032
-
Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation.Pharmacol Res. 2018 Jun;132:149-159. doi: 10.1016/j.phrs.2018.04.019. Epub 2018 Apr 23. Pharmacol Res. 2018. PMID: 29698794 Review.
-
Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke.Stroke. 1997 Feb;28(2):311-5. doi: 10.1161/01.str.28.2.311. Stroke. 1997. PMID: 9040681 Review.
Cited by
-
Aging-Related Decline of Glutathione Peroxidase 3 and Risk of Cardiovascular Events in Patients With Atrial Fibrillation.J Am Heart Assoc. 2016 Sep 8;5(9):e003682. doi: 10.1161/JAHA.116.003682. J Am Heart Assoc. 2016. PMID: 27609361 Free PMC article.
-
A Comment on 'Screening for Obstructive Sleep Apnea Before Coronary Angiography'.Clin Respir J. 2025 Apr;19(4):e70077. doi: 10.1111/crj.70077. Clin Respir J. 2025. PMID: 40223179 Free PMC article. No abstract available.
-
Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation.Curr Cardiol Rep. 2015 Aug;17(8):64. doi: 10.1007/s11886-015-0615-7. Curr Cardiol Rep. 2015. PMID: 26104508 Review.
-
Mediterranean Diet: A Tool to Break the Relationship of Atrial Fibrillation with the Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease.Nutrients. 2022 Mar 16;14(6):1260. doi: 10.3390/nu14061260. Nutrients. 2022. PMID: 35334916 Free PMC article. Review.
-
C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP.Sci Rep. 2017 Jun 19;7(1):3797. doi: 10.1038/s41598-017-03679-9. Sci Rep. 2017. PMID: 28630469 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical